Kornimate/medical-research-clean huggingface dataset:
assessing the efficacy of intravenous acetaminophen versus the oral formulation for perioperative pain treatment

Conditions: Postoperative Pain

Summary: to compare oral (po) to intravenous (iv) acetaminophen with postoperative pain scores, and consumptions of opiates, among orthopedic surgery patients undergoing total knee replacement with spinal anesthesia. our hypothesis is that iv acetaminophen patients will have improved analgesia, less opioid consumption, a lower percentage of patients rescuing, or a longer time to first rescue with iv acetaminophen. the investigators will compare the efficacies of oral and intravenous acetaminophen for postoperative pain control, and utilization of opiates as rescue agents.

intravenous acetaminophen has rapid onset and potent analgesic properties. recent studies have shown several advantages of using intravenous acetaminophen perioperatively. however, due to its relatively high cost and limited clinical data concerning its efficacy compared with other agents, physicians are hesitant to use intravenous acetaminophen in the perioperative period. 174 adult patients from the orthopedic surgeons undergoing total knee replacement with spinal anesthesia will be enrolled. the study will be double blind, randomized; placebo controlled comparing oral and iv acetaminophen to each other and a control (placebo). at the time patients arrive in the post-anesthesia care unit (pacu), group 1 will receive iv 1 gram acetaminophen, and po placebo; group 2 will receive po 1 gram acetaminophen and iv placebo; group 3 will receive iv placebo and po placebo. the primary outcome that will be assessed is pain scores, which will be recorded by using the numeric rating scale 1-10 every 15 minutes. secondary outcomes include time to rescue analgesia (measured in minutes), time to pacu discharge (measured in minutes), and the total amount of hydromorphone (po or iv) consumed within 6 hours postoperatively for adequate analgesia (total measured in milligrams) will be collected. the difference in pain scores will be assessed by a chi-square test. a multivariable regression model will be performed with the clinical and statistically significant variables to remove confounding.

Eligibility criteria:
inclusion criteria: * patients undergoing total knee replacement * successful spinal placement * ≥18 years old exclusion criteria: * failed spinal anesthesia * chronic opiate users * liver disease patients * allergy/hypersensitivity to acetaminophen * patients with baseline dementia * patients weighing less than 50kg, history of alcohol dependence, renal impairment, opiate allergy, and pregnancy.

Keywords: acetaminophen total knee replacement numeric rating scale
pain characteristics after total laparoscopic hysterectomy

Conditions: Myoma of Uterus

Summary: laparoscopic operative procedures have revolutionized gynecological surgery. these have several advantages: a smaller and more cosmetic incision, reduced blood loss and shorter postoperative stay, which cuts down on hospital costs. however, postoperative pain continues to be one complication, which results in an unpleasant experience for the patient and at times causes a delayed discharge. there are few studies about pain characteristics as one of laparoscopic hysterectomy complications. the purpose of this study is to investigate the prevalence and characteristics of shoulder pain, headache, abdominal pain, and back pain in patients undergoing total laparoscopic hysterectomy.


Eligibility criteria:
inclusion criteria: * asa i or ii * age \>=20, \<= 80 years * female * patients undergoing elective total laparoscopic hysterectomy exclusion criteria: * age \ 80 years * abnormal mental status * drug abuse * chronic alcoholism * immunosuppressants or steroid user

Keywords: pain total laparoscopic hysterectomy
efficacy and safety of kinetin 0.1% for treatment of skin photoaging

Conditions: Cutaneous Photoaging

Summary: the purpose of the study is to evaluate the change in the severity and clinical signs of skin photoaging among filipino patients using kinerase cream (kinetin 0.1%). this study will recruit 132 subjects from dermatological clinics in a tertiary hospital in the philippines for a period of 3 months (12 weeks). changes in severity will be documented using physician evaluation, self-evaluation, and through visia complexion analysis system.

this study is a single-arm, open-label, split-face trial in subjects with mild to moderate photoaged facial skin. the study will enroll around 132 subjects from selected private dermatology clinics in a tertiary hospital in the philippines. patients from selected private dermatology clinics of a tertiary hospital will be screened and recruited to participate. they will be provided a written consent form (appendix i) before they will be included in the study. following enrollment, subjects will return for outpatient visits at weeks 4, 8, and 12 for assessment. the whole study will be conducted from july 2013 to november 2013. the first month would involve recruitment of patients. qualified patients will start the 12-week treatment period and will be asked to follow up every 4 weeks. the last two months would be for data analysis, interpretation and writing of the scientific report.

Eligibility criteria:
inclusion criteria: * filipino and asian female subjects from private clinics of a tertiary hospital in the philippines older than 35 years of age and less than 65 years of age. * subjects with mild to moderate cutaneous photoaging as assessed by the investigator's assessment 6-point scale. * subjects willing to sign an informed consent and adhere to all protocol requirements. exclusion criteria: * suspected porphyria, systemic or cutaneous lupus erythematosus, or any other photosensitizing disorder or drug-induced photosensitization * chronic or recurring skin disease or disorder * any active infectious skin disorder (herpes simplex, molluscum contagiosum, and facial warts) * skin cancer of the facial tissues * any laser/ipl/ chemical peel in the 2 months preceding the screening visit * history of isotretinoin use, 6 months prior to the screening disease * topical tretinoin or adapalene in the 2 months prior to the screening visit * used topical alpha-hydroxy acid skincare products in the month preceding the screening visit * on any anti-aging products and who wish to continue use of their products * requiring concurrent treatment that would interfere with the study assessments * pregnant or lactating females
isokinetic training versus treadmill training on muscle strength and gait in children with lower limb burns

Conditions: Burned

Summary: burn wounds are one of the most complexes and dramatic of all injuries, it produces a direct local tissue destruction and damage. in addition, burn wounds may continue to destroy tissue and muscles, exercise therapy stimulates the early expression of angiogenesis-related growth factors so it results in new vessel in-growth that improves blood supply, increases cell proliferation, accelerates tissue regeneration and healing and regain muscle strength

to evaluate the efficacy of isokinetic training against treadmill training in improving muscle strength and gait in children having lower limb burns. methods: sixty children from both genders (boys and girls) who were complaining from 2nd degree lower limb burns with ≥30 percent of their total body surface area (tbsa) participated in this study, their ages ranged from 8 to 16 years and they were randomized into three groups of same number (a, b and c). groups (a) received conventional physical therapy program, group (b) received the same conventional physical therapy program of group (a) with trained to use the isokinetic device while group (c) received the same conventional physical therapy program of group (a and b) and used treadmill training. the children participated in this study were assessed by hand-held dynamometer (hhd) and balance master system (bms). they were evaluated before and after the treatment program three sessions per week for 12 consecutive weeks.

Eligibility criteria:
inclusion criteria: * children aged between 8 to 16 year * complaining from 2nd degree lower limb burns (≥30 % of their tbsa). * capable of standing and walking independently. * clinically and medically stable. * sufficient cognition demonstrating understanding the requirements of the study. * no history of lower extremity surgery. exclusion criteria: * visual and/or auditory defects. * significant shortening and/or deformity of lower extremities. * other neurological problems that affect balance or mentality (e.g. epilepsy). * advanced radiographic changes include (bone destruction, bony ankylosis, knee joint sublaxation and epiphysial fracture). * congenital or acquired skeletal deformities in the lower limbs. * cardiopulmonary dysfunction.

Keywords: burn; children; isokinetic training; treadmill training
a study comparing the effects and safety of dulaglutide with insulin glargine in type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (oam) (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended by their healthcare providers.


Eligibility criteria:
inclusion criteria: * have type 2 diabetes mellitus for at least 6 months * have been taking metformin and/or a sulfonylurea for at least 3 months before screening and have been on a stable therapeutic dose for at least 8 weeks * glycosylated hemoglobin (hba1c) value of ≥7.0% to ≤11.0% * adult men or adult non-pregnant, non-breastfeeding women * body mass index (bmi) of ≥19.0 to ≤35.0 kilograms/square meter (kg/m\^2) * stable weight (±5%) ≥3 months prior to screening exclusion criteria: * have type 1 diabetes mellitus * have previous treatment with a glucagon-like peptide-1 (glp-1) receptor agonist, glp-1 analog, or any other incretin mimetic * have treatment with dipeptidyl peptidase-iv (dpp-iv) inhibitor, an alpha-glucosidase inhibitor (agi), thiazolidinedione (tzd), or glinide * have gastric emptying abnormality * have cardiac disorder defined as unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, arrhythmia, transient ischemic attack, or stroke * have poorly controlled hypertension (systolic blood pressure above 160 millimeter of mercury\[mmhg\] or diastolic blood pressure above 95 mmhg) * have impaired liver function * have impaired kidney function * have history of chronic pancreatitis or acute pancreatitis * have a serum calcitonin ≥20 picograms per milliliter (pg/ml) * have a personal or family history of medullary c-cell hyperplasia, focal hyperplasia, carcinoma, or multiple endocrine neoplasia type 2 (men 2)
epibone study: a prospective study on feasibility, safety and accuracy

Conditions: Bone Metastases; Fractures, Bone; Bone Tumor

Summary: interventional clinical study to obtain performance and safety data of the epione® device when used for bone percutaneous procedures.


Eligibility criteria:
inclusion criteria: 1. patient ≥18 years, 2. patient with indication of ct-guided percutaneous bone procedure under general anaesthesia validated at a multidisciplinary consultation meeting, 3. patient who has signed an informed consent form, 4. patient covered by a social security system, non-inclusion criteria: 1. patient with contraindication to general anaesthesia, 2. patient undergoing a procedure without appropriate breathing control, 3. patient scheduled for ct-guided percutaneous procedures on head and neck, including skull and cervical vertebrae, 4. patient with medical, psychosocial or emotional conditions unable to fully understand the study protocol, give an uninfluenced informed consent, or meet the study requirements during its whole duration. 5. pregnant or breast-feeding women, 6. patient under legal protection (tutorship, guardianship, ...), 7. patient already participating in another interventional clinical study.

Keywords: robotic robotic guidance percutaneous ct-guided bone consolidation thermal ablation
optimizing medication therapy for patients recently discharged from hospital

Conditions: Chronic Disease

Summary: patients who are discharged from hospital can be overwhelmed when they suddenly have to manage new conditions or medications. these changes can be particularly difficult for people on many medications or with multiple health conditions. there is a real risk that this will lead to emergency room visits, hospital readmission, and even death. in addition to endangering patients, these adverse events are very costly to the healthcare system. the good news is that these events can be preventable if patients receive care that is better coordinated. patient-oriented research will be conducted to determine if a pharmacist-led medication therapy management service can improve health outcomes of 'medically complex' patients transitioning from acute to primary care in newfoundland and labrador (nl). this a more comprehensive service than their community pharmacist would normally provide. the program will use a new pharmacist clinic service to provide care and support which does not currently exist for patients in nl after they leave hospital. after discharge, patients will be randomly divided into two groups: one group will receive care as usual from their doctor; the other group will have their medications assessed by a clinic pharmacist within one week of hospital discharge along with their usual care from their doctor. the two groups will be compared to determine whether specialized pharmacist services after hospital discharge is satisfactory to patients/providers, improves patient health, and reduces emergency room visits, hospital readmissions, and repeat trips to the doctor. if successful, this project will help ensure that patients are taking the right medications in the right way, improving individual health and making better use of healthcare system resources.


Eligibility criteria:
inclusion criteria: 1. 50 years of age or older 2. admitted to a general medicine ward 3. take 5 or more chronic medications exclusion criteria: 1. discharge to a long term care facility 2. life expectancy less than 3 months 3. have entered palliative care 4. cognitive impairment (unless a responsible caregiver can provide consent and assist in participation) 5. non-english speaking 6. unable to provide informed consent
complications after lumpectomy, sentinel node and radiotherapy in breast cancer patients and physiotherapy care

Conditions: Breast Neoplasm

Summary: to make an inventory of the physiotherapeutic care and the post-operative complications of patients who have undergone lumpectomy, sentinel node and radiotherapy treatment. the investigators expect to see a lack of consultation of physiotherapists by patients despite a significant number of complications, impacting the quality of life.

this study is observational and descriptive. for this purpose, patients meeting the inclusion and non-inclusion criteria can answer, if they wish, to an online questionnaire after having read the information and non-opposition letter.

Eligibility criteria:
inclusion criteria: * volunteer patients * patients with a good command of french in order to understand the letter of information and the questionnaire. * patients treated at the "couple enfant hospital" in grenoble. we have chosen to take patients who have been operated on at least 3 months ago (average time of end of radiotherapy). exclusion criteria: * patient having undergone a mastectomy or chemotherapy * patient with difficulties understanding, expressing or reading the french language * vulnerable patient or patient with impaired cognitive capacities (dementia, confusion) * patient subject to a legal protection measure or out of state to express her opposition (guardianship, curatorship)

Keywords: postoperative complications physiotherapy rehabilitation lumpectomy sentinel node radiotherapy
el faro: addressing mental health inequities among latinx children with adhd in durham

Conditions: ADHD; Psychiatric Health

Summary: study team members from el futuro in durham, north carolina have created an intervention called el faro. el faro helps latinx families of children with adhd understand and cope with the stress and difficulties presented by the disorder. we propose to develop a community-engaged research partnership between el futuro and the duke adhd program that aims to pilot-test an adapted el faro treatment.


Eligibility criteria:
inclusion criteria: * child is between the ages of 6 to 12 years * child has received a previous diagnosis of adhd in the community based on caregiver report * adhd rating scale (parent rating scale of adhd symptoms) symptom severity score of 24 or higher * child meets dsm-5 criteria for adhd (any presentation) based on the mini * generally healthy (i.e., no major medical problems that will interfere with study participation) * caregiver's willingness to keep any current psychiatric medication regimen for child diagnosed with adhd constant throughout the study duration * caregiver age 18 years and older * caregiver self-identify as latinx exclusion criteria: * caregiver's child has previous diagnosis of autism, schizophrenia, or bipolar disorder in the community per caregiver report or other psychiatric disorder that is primary to adhd or may interfere with study involvement. * caregiver unable to attend all el faro sessions * plan to initiate new adhd treatment for identified child with adhd during study participation (previously established adhd treatments are allowable) * other concerns besides adhd that would interfere with study participation according to the study team.

Keywords: psychiatric health children adhd latinx community
structured mobile technology based lifestyle program vs usual care for patients with non-alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease; Non-alcoholic Steatohepatitis

Summary: this study will look at physical activity and nutrition in patients with non-alcoholic fatty liver disease (nafld) or non-alcoholic steatohepatitis (nash). the researchers will see if providing patients with nafld/nash with specific physical activity and nutrition feedback as an addition to their usual clinical care helps them to lose weight and improve liver-related parameters.


Eligibility criteria:
inclusion criteria: * diagnosis of non-alcoholic fatty liver disease (nafld) or non-alcoholic steatohepatitis (nash) * access to mobile phone/tablet/ or computer compatible with fitbit application and ability to use said device and application * ability to participate in physical activity exclusion criteria: * any other form of liver disease( alcohol related liver disease; viral hepatitis, autoimmune liver disease, hereditary forms of liver disease, etc.) * history of decompensated cirrhosis * plans for invasive procedures or other regimented lifestyle programs for weight reduction * cardiovascular event in the previous 3 months

Keywords: mobile technology weight nutrition
wearable neuromodulation device for the treatment of alzheimer's disease

Conditions: Mild Alzheimer's Disease

Summary: this is a double- blind, randomized controlled trial with an open label extension designed to evaluate the safety and potential efficacy of a non-invasive brainstem neuromodulation device for treating symptoms associated with alzheimer's disease (ad).

up to 45 participants will first enter the double-blind, randomized controlled trial during which they will self-administer treatments twice daily in the home setting over 24 weeks with one of two investigational treatment modes. participants who complete the randomized controlled trial will then enter the open label extension where all participants will self-administer twice-daily treatments over 24 weeks using the same investigational treatment mode that was reported to show benefit in a previous clinical trial in another neurodegenerative disease.

Eligibility criteria:
inclusion criteria: * adult participants (aged 65 - 85 years inclusive) diagnosed with probable alzheimer's disease dementia . * willing and able to comply with study requirements. * have a study partner who sees the participant for more than three hours a day, 5x per week and is that is willing to consent and participate in the trial. * anticipation that the participant is able to remain on a stable regimen of medications used for the management of alzheimer's disease and will not introduce new medications used to treat alzheimer's disease during the study. * participant and study partner must both be fully vaccinated from covid-19 prior to the study screen exclusion criteria: * were diagnosed with probable alzheimer's disease prior to 65 years of age. * has experienced a heart attack, angina, or stroke within the past 12 months or a transient ischemic attack (tia) within the past 6 months. * are being treated with another neurostimulation device * experience frequent falls * works night shifts. * have unresolved complications from a previous surgical procedure at the baseline visit, such as swelling or persistent pain, that requires medical intervention. * have active ear infections, or other significant ear problems. * have a recent history of frequent ear infections * have a cochlear implant or hearing aids that cannot be easily/reliably removed for treatment. * have chronic tinnitus. * have previously been diagnosed with traumatic brain injury with ongoing sequela. * history of medication-refractory depression or bipolar disorder in the past three years. * history of schizophrenia. * participation in an interventional clinical trial for any medical or psychiatric indications within 3 months of the screening visit, or at any time during the study.

Keywords: open label extension medical devices non-invasive brain stimulation randomized controlled trial brainstem
familial aggregation and biomarkers in rem sleep behaviour disorder.

Conditions: REM Sleep Behavior Disorder

Summary: in this cohort study, the investigators aim to study the familial aggregation of rem sleep behavior disorder (rbd) and compare the differences in major biomarkers of neurodegeneration, including percentage of emg activity during rem sleep, cognitive functions, autonomic dysfunction, and psychiatric disorders, between unaffected first degree relatives of rbd cases and non-rbd controls.

rem sleep behavior disorder (rbd) is a parasomnia characterized by abnormal behavioral manifestations during rem sleep. previous case-control studies and prospective studies have documented the progression of α-synucleinopathy neurodegeneration in relation to rbd and have identified some biomarkers of predicting neurodegeneration in patients with irbd, such as olfactory dysfunction, color vision deficit, autonomic dysfunction, tonic emg activity during rem sleep, and psychiatric disorder. however, these biomarkers might precede the onset of rbd, as a result, searching for biomarkers for the neurodegeneration before rbd onset is helpful to map the progression of neurodegeneration. in this regard, the investigators aim to study the familial aggregation of rbd and its core features, and compare the differences in major biomarkers of neurodegeneration, including percentage of emg activity during rem sleep, cognitive functions, autonomic dysfunction, and psychiatric disorders, between unaffected first degree relatives of rbd cases and non-rbd controls.

Eligibility criteria:
inclusion criteria: 1. chinese aged 40 or above; 2. being capable of giving informed consent for participation of the study; 3. sex matched between relatives from probands and controls. exclusion criteria: 1. aged 39 or below; 2. not capable of giving informed consent for participation of the study